ArticleAnnals of pediatric cardiology
Bile acid dysregulation in Fontan circulation: A Parallel to hyperglycemia in diabetes?
Article in Annals of pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survivors of the Fontan circulation increasingly develop late multisystem complications, including liver disease, cardiac dysfunction, and frailty, despite stable hemodynamics. Emerging metabolomic data demonstrate chronically elevated circulating bile acids in Fontan patients, implicating a previously underrecognized metabolic contributor to disease progression. Drawing parallels with diabetes mellitus, in which chronic hyperglycemia drives silent organ injury through metabolic memory, we propose that persistently elevated bile acids act as a similar pathogenic driver in the Fontan circulation. Bile acid-mediated mitochondrial dysfunction, inflammation, and fibrosis may imprint early cellular injury that manifests clinically years later. This framework highlights the potential importance of early bile acid surveillance and timely metabolic intervention to prevent irreversible end-organ damage and improve long-term outcomes in Fontan patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.